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Abstract: In the past decade, the world has experienced a large increase in the number of novel compounds 
appearing on the illicit drug market for recreational purposes. Such substances are designed to circumvent 
governmental regulations; the illegal drug manufacturers take a known psychoactive compound reported 
in the scientific literature and slightly modify its chemical structure in order to produce analogues that will 
mimic the pharmacological activity of the original substance. Many of these novel substances are sold via 
the Internet. Among the various chemical classes, synthetic cannabinoid receptor modulators, commonly 
referred to as “synthetic cannabinoids” have been at the forefront, as demonstrated by the frequency of 
drug seizures, numerous severe toxic effects, and fatalities associated with some of these substances. This 
review presents the chemical structures of relevant synthetic cannabinoids and describes their mechanism 
of action, pharmacological features, metabolic pathways, and structure-activity relationships. It illustrates 
the approaches used in forensic testing, both for bulk analysis (drug seizures) and for analytical toxicology 
(biological matrices) and discusses aspects of regulation surrounding this drug class. This report is intended 
to provide pertinent information for the purposes of informing scientific, medical, social, and governmental 
bodies about this ever-evolving recreational drug class and the challenges it poses worldwide.
Keywords: biological samples; drug analysis; metabolites; novel psychoactive substances; public health; 
synthetic cannabinoids.
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1   Introduction
Novel Psychoactive Substances (NPS), also known as “legal highs” or “designer drugs”, are a broad class 
of recreational drugs that have recently emerged on the illicit drug market whose chemical nature may be 
similar to well-known substances of abuse. However, many of these compounds are not novel, as some were 
 synthesized in research laboratories up to 30 years ago [1]. Although abandoned by researchers due to their 
psychotropic effects or other unfavorable properties, they have been re-evaluated by illegal drug manufactur-
ers for recreational purposes [2–4]. Many articles published in scientific journals describe synthetic pathways 
and the preliminary pharmacological profiles for these substances and their analogues and can be easily 
accessed; thus, published data is often misappropriated for use in the drug abuse community [5, 6].
To circumvent legislative bans, NPS are structurally modified to differ from the original drug that they are 
pharmacologically related to. They are often sold in packages labeled “not for human consumption” to evade 
analogue provisions. After repeated drug seizures by law enforcement and forensic investigations revealing target 
compounds, bans to outlaw the associated substances are typically put in place by the appropriate legislative 
authorities. It is well known from structure-activity relationship(s) (SAR) studies that even minor modification of 
a lead compound may result in dramatic pharmacokinetic and/or pharmacodynamic changes, with the potential 
to cause life-threatening adverse effects [7, 8]; therefore, NPS pose a severe worldwide public health threat.
NPS are generally categorized according to their chemical structures and their mechanism of action. 
Some of the major classes of NPS include, but are not limited to, synthetic opioids, synthetic cannabinoids, 
phenylethylamines, synthetic cathinones, tryptamines, piperazines, and designer benzodiazepines  (see Fig. 
1). The purpose of this work is to provide up-to-date information about the synthetic cannabinoid class, 
including selected chemical structures, International Union of Pure and Applied Chemistry (IUPAC) chemical 
names, SAR, metabolism and expected biological effects, their identification in forensic analysis, as well as 
approaches to government regulations in selected countries.
Synthetic cannabinoid receptor modulators, commonly referred to as “synthetic cannabinoids” (SCs), are 
substances of various chemical subclasses that were originally synthesized to study their activity at the can-
nabinoid receptors (CB1 and CB2) and their potential use as therapeutic agents [9]. Many of these substances 
mimic the effects of Δ9-tetrahydrocannabinol (Δ9-THC, THC), (see Fig. 2), the main psychoactive component of 
cannabis. Consequently, some of the most potent SCs have, in recent years, become popular for recreational 
use as “legal” marijuana substitutes. The most popular forms of SC products typically contain a matrix of inert 
botanical material (e.g. Pedicularis densiflora, Nymphacea caerulea, Leonotis leonurus, Leonurus sibiricus, Car-
navalia maritime, and Zornia latifolia) that has been spiked with the psychoactive drug for smoking [9]. Com-
pounds are dissolved in an organic solvent, such as acetone, or in alcohol, and are subsequently sprayed onto 
the plant matrix and allowed to dry prior to packaging. Products have been branded and marketed as “Spice”, 
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“K2”, “synthetic marijuana”, and “fake weed”, to name a few [10, 11]. The foil packets containing the drug-
laced botanical materials are typically shiny in appearance and many have common cartoon or movie charac-
ters on the packet to make them more attractive, especially for the purposes of drawing younger consumers [9]. 
Other forms of SC products include powders, capsules, and liquids that could be used in e-cigarettes [9, 12, 13].
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Fig. 1: Chemical structures of selected NPS: Acetyl fentanyl, N-[1-(2-phenylethyl)piperidine-4-yl]-N-phenylacetamide, a 
synthetic opioid (1); JWH-018, naphthalen-1-yl(1-pentyl-1H-indol-3-yl)methanone, a synthetic cannabinoid (2); 25I-NBOMe, 
2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, a phenethylamine derivative (3); Mephedrone, rac-
2-(methylamino)-1-(4-methylphenyl)propan-1-one, a synthetic cathinone (4); DMT, 2-(1H-indol-3-yl)-N,N-dimethylethan-1-amine, 
a tryptamine derivative (5); N-Benzylpiperazine, 1-benzylpiperazine, a piperazine derivative (6); Clonazolam, 6-(2-chlorophenyl)-
1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine, a designer benzodiazepine (7).
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Fig. 2: Chemical structures of endogenous, natural, and synthetic cannabinoid receptor ligands: Oleamide, [(9Z)-
octadec-9-enamide, an endogenous cannabinoid ligand (1); Anandamide, [(5Z,8Z,11Z,14Z)-N-(2-hydroxyethyl)]
icosa-5,8,11,14-tetraenamide, a fatty acid-derived endogenous neurotransmitter (2); Δ9-THC, (6aR,10aR)-6,6,9-tri-
methyl-3-pentyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol, a natural cannabinoid (3); HU-210, (6aR,10aR)-
9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol a synthetic can-
nabinoid (4); CP 47,497, 2-[(1S,3R)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol, a synthetic cannabinoid (5); JWH-018, 
naphthalen-1-yl(1-pentyl-1H-indol-3-yl)methanone, a synthetic cannabinoid (6); AB-FUBINACA, N-[(2S)-1-amino-3-methyl-
1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H indazol-3-carboxamide, a synthetic cannabinoid (7); XLR-11, [1-(5-fluoropentyl)-
1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone, a synthetic cannabinoid (8).
Brought to you by | King's College London
Authenticated
Download Date | 1/24/19 4:10 PM
1258      V. Abbate et al.: Novel psychoactive drugs of abuse: synthetic cannabinoids
Over the last decade, an increase in the variety of chemical subclasses of SCs identified in these prod-
ucts has been observed, and these compounds have become increasingly potent. Many SCs were found to 
have stronger binding affinities to CB1 and/or CB2 receptors than Δ9-THC, inducing stronger physiological 
responses. Their recreational intake led to significant increases in adverse intoxication, posing challenges to 
the clinical and forensic communities. Acute and chronic intake have elicited an array of undesired effects 
including psychotic reactions, cardiac events, seizures, tissue injury, and death [14–17].
2   Synthetic cannabinoids history and nomenclature
In the early 1960s, the chemical structure of Δ9-THC was determined by Gaoni and Mechoulam [18, 19]. This 
structural elucidation was significant, because the components of marijuana had been long studied, but, 
until this point, no characterization of the major psychoactive compound had been performed. In the sub-
sequent decades, more findings included the identification of the structure and activity of the CB1 and CB2 
cannabinoid receptors, as well as the endogenous cannabinoid receptor ligands (endocannabinoids) anan-
damide and oleamide (Fig. 2); SCs bind to these receptors and mimic some of the pharmacological effects of 
Δ9-THC [1, 9, 20].
In addition to natural and endogenous cannabinoids, medicinal chemists and university researchers 
have performed a significant amount of investigation on synthetic compounds that bind to the CB receptors. 
The details of many of these studies have been reported in peer-reviewed literature and in pharmaceutical 
patents [21, 22]. Over the last ten years, SCs abuse has increased worldwide, posing many challenges to the 
medical and forensic communities [9, 14, 15]. Adding to the challenge is the expansion of the structural diver-
sity of SCs over the years (Fig. 2). Approximately 160 different SCs have been reported by the European Moni-
toring Centre for Drugs and Drug Addiction (EMCDDA) since 2008 [23]. However, not all of these substances 
were prevalent in clinical and forensic casework and even fewer have been presented in medical and forensic 
peer-reviewed literature. The typical time on the illicit drug market for a new SC varies, with new compounds 
quickly replacing “older generation” substances after they become banned [15, 23, 24].
In Fig. 2, structures of endogenous, natural and synthetic cannabinoids are presented as a means of eval-
uating the structural development and historical evolution of cannabinoid compounds. The first generation 
of SCs were identified in products in Germany and Japan in 2008–2009 and were typically of the cyclohexyl-
phenol (e.g. CP 47,497) or naphthoylindole (e.g. JWH-018) class (Tables 1 and 2) [25–28]. In subsequent years 
Table 1: Cyclohexylphenols.
OH
OH
R2
R1
Common name   Chemical name   R1   R2
CP 47,497   2-[(1S,3R)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol   methyl  H
CP 47,497 (C6)   2-[(1S,3R)-3-hydroxycyclohexyl]-5-(2-methylheptan-2-yl)phenol   H   H
CP 47,497 (C8) 
(Cannabicyclohexanol)
  2-[(1S,3R)-3-hydroxycyclohexyl]-5-(2-methylnonan-2-yl)phenol   ethyl   H
CP 47,497 (C9)   2-[(1S,3R)-3-hydroxycyclohexyl]-5-(2-methyldecan-2-yl)phenol   propyl   H
CP 55,940   2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-
methyloctan-2-yl)phenol
  methyl  3-hydroxypropyl
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Table 2: Naphthoylindoles.
R1
O
N
R3
R2
Common name   Chemical name   R1   R2   R3
AM-1220   [1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl](naphthalen-
1-yl)methanone
  H   (1-methylpiperidin-
2-yl)methyl
  H
AM-1220 azepane 
isomer
  [1-(1-methylazepan-3-yl)-1H-indol-3-yl](naphthalen-1-yl)
methanone
  H   1-methylazepan-
3-yl
  H
AM-2201   [1-(5-fluoropentyl)-1H-indol-3-yl](naphthalen-1-yl)methanone   H   5-fluoropentyl   H
AM-2232   5-[3-(naphthalene-1-carbonyl)indol-1-yl]pentanenitrile   H   pentanenitrile   H
EAM-2201   (4-ethylnaphthalen-1-yl)(1-(5-fluoropentyl)-1H-indol-3-yl)
methanone
  ethyl   5-fluoropentyl   H
JWH-007   (2-methyl-1-pentyl-1H-indol-3-yl)(naphthalen-1-yl)methanone   H   pentyl   methyl
JWH-015   (2-methyl-1-propyl-1H-indol-3-yl)(naphthalen-1-yl)methanone   H   propyl   methyl
JWH-018 (AM678)   (naphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone   H   pentyl   H
JWH-018 N-(5-
chloropentyl)
  [1-(5-chloropentyl)-1H-indol-3-yl](naphthalen-1-yl)methanone   H   5-chloropentyl   H
JWH-019   (1-hexyl-1H-indol-3-yl)(naphthalen-1-yl)methanone   H   hexyl   H
JWH-022   (naphthalen-1-yl)[1-(pent-4-en-1-yl)-1H-indol-3-yl]methanone   H   pent-4-en-1-yl   H
JWH-071   (1-ethyl-1H-indol-3-yl)(naphthalen-1-yl)methanone   H   ethyl   H
JWH-073   (1-butyl-1H-indol-3-yl)(naphthalen-1-yl)methanone   H   butyl   H
JWH-073 
(4-methylnaphtyl) 
(JWH-122 N-butyl 
analogue)
  (1-butyl-1H-indol-3-yl)(4-methylnaphthalen-1-yl)methanone   methyl   butyl   H
JWH-081   (4-methoxynaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone   methoxy   pentyl   H
JWH-098   (4-methoxynaphthalen-1-yl)(2-methyl-1-pentyl-1H-indol-3-yl)
methanone
  methoxy   pentyl   methyl
JWH-116   (2-ethyl-1-pentyl-1H-indol-3-yl)(naphthalen-1-yl)methanone   H   pentyl   ethyl
JWH-122   (4-methoxynaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone   methyl   pentyl   H
JWH-122 
(5-fluoropentyl) 
(MAM2201)
  [1-(5-fluoropentyl)-1H-indol-3-yl](4-methylnaphthalen-1-yl)
methanone
  methyl   5-fluoropentyl   H
JWH-149   (2-methyl-1-pentyl-1H-indol-3-yl)(4-methylnaphthalen-1-yl)
methanone
  methyl   pentyl   methyl
JWH-182   (1-pentyl-1H-indol-3-yl)(4-propylnaphthalen-1-yl)methanone   propyl   pentyl   H
JWH-193   (4-methylnaphthalen-1-yl){1-[2-(morpholin-4-yl)ethyl]-1H-indol-
3-yl}methanone
  methyl   2-(morpholin-4-yl)
ethyl
  H
JWH-198   (4-methoxynaphthalen-1-yl){1-[2-(morpholin-4-yl)ethyl]-1H-indol-
3-yl}methanone
  methoxy   2-(morpholin-4-yl)
ethyl
  H
JWH-200   {1-[2-(morpholin-4-yl)ethyl]-1H-indol-3-yl}(naphthalen-1-yl)
methanone
  H   2-(morpholin-4-yl)
ethyl
  H
JWH-210   (4-ethylnaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone   ethyl   pentyl   H
JWH-211   (4-ethylnaphthalen-1-yl)-(2-methyl-1-propylindol-3-yl)methanone   ethyl   propyl   methyl
JWH-387   (4-bromonaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone   Br   pentyl   H
JWH-398   (4-chloronaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone   Cl   pentyl   H
JWH-412   (4-fluoronaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone   F   pentyl   H
MAM-2201   [1-(5-fluoropentyl)-1H-indol-3-yl](4-methylnaphthalen-1-yl)
methanone
  methyl   5-fluoropentyl   H
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(2011–2013), classes such as the tetramethylcyclopropanoylindole (e.g. XLR-11, Table 5), indazole carboxam-
ide (e.g. AKB48, Table 8), and halogenated naphthoylindole (e.g. AM-2201, Table 2) classes appeared on the 
market internationally [9, 24, 29]. Many more classes of compounds were identified during this time and con-
tinue to emerge (through 2017), including benzoylindoles (Table 3), phenylacetylindoles (Table 4), various 
alkoylindoles (Table 5), indole carboxylates (Table 6), indole carboxamides (Table 7), and an even greater 
number of indazole carboxamides (Table 5) [30–35]. Some examples of compounds of these classes identified 
in seized materials and reported in the literature include, but are not limited to, the following: RCS-4, JWH-
250, AB-001, PB-22, MDMB-CHMICA, AB-FUBINACA, MMB-FUBINACA (AMB-FUBINACA) and 5-Fluoro ADB 
[36, 37].
The naming of SC compounds is not harmonized and several conventions are utilized. Initially, each 
series was typically named with a two- or three-letter abbreviation associated with the laboratory in 
which they were synthesized, followed by a three- or four-figure number identifying them within that 
series. For example, JWH-018 was synthesized in the laboratory of John W. Huffman (“JWH”) of Clemson 
University, and CP 47,497 was synthesized by Pfizer (“CP”, for Charles Pfizer). However, XLR-11 is a type 
of rocket engine from the 1960s and AKB48 is a Japanese female band [9]. As more compounds began to 
appear on the market, naming conventions shifted in a new direction; authors of literature in this area 
gravitated towards use of the formal IUPAC nomenclature, with abbreviated common names derived from 
the IUPAC name. For example, the name ADB-FUBINACA is based on the chemical name N-(1-amino-
3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide [15]. It should be noted that 
the common name of a compound may or may not be related to the structure or IUPAC chemical name 
Table 3: Benzoylindoles.
R2
R1
O
NR4
R3
Common name   Chemical name   R1   R2   R3   R4
AM-2233   (2-iodophenyl){1-[(1-methylpiperidin-2-yl)methyl]-1H-
indol-3-yl}methanone
  H   I   (1-methylpiperidin-
2-yl)methyl
  H
AM-679   (2-iodophenyl)(1-pentyl-1H-indol-3-yl)methanone   H   I   pentyl   H
AM-694   [1-(5-fluoropentyl)-1H-indol-3-yl](2-iodophenyl)
methanone
  H   I   5-fluoropentyl   H
AM-694 (chloro)   [1-(5-chloropentyl)-1H-indol-3-yl](2-iodophenyl)
methanone
  H   I   5-chloropentyl   H
RCS-4 (SR-19; OBT-
199; BTM-4; E-4)
  (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone   methoxy  H   pentyl   H
RCS-4 ortho 
isomer (RCS-4 
2-methoxyisomer)
  (2-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone   H   methoxy  pentyl   H
RCS-4 butyl homolog   (1-butyl-1H-indol-3-yl)(4-methoxyphenyl)methanone   methoxy  H   butyl   H
WIN 48,098 
(Pravadoline)
  (4-methoxyphenyl)-[2-methyl-{1-[2-(morpholin-4-yl)
ethyl]-1H-indol-3-yl}(naphthalen-1-yl)methanone
  methoxy  H   2-(morpholin-4-yl)
ethyl
  methyl
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Table 5: Alkoylindoles.
O
N
R1
R2
Common name   Chemical name   R1   R2
A-796260   {1-[2-(morpholin-4-yl)ethyl]-1H-indol-3-yl}
(2,2,3,3-tetramethylcyclopropyl)methanone
  2-(morpholin-4-yl)
ethyl
  2,2,3,3-tetramethylcyclopropyl
A-834,735   [1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-
indol-3-yl](2,2,3,3-tetramethylcyclopropyl)
methanone
  tetrahydro-2H-
pyran-4-yl methyl
  2,2,3,3-tetramethylcyclopropyl
AB-001   adamantan-1-yl(1-pentyl-1H-indol-3-yl)
methanone
  pentyl   adamantan-1-yl
AB-005   [1-(1-methylpiperidin-2-yl)methyl-1H-
indol-3-yl](2,2,3,3-tetramethylcyclopropyl)
methanone
  1-methylpiperidin-
2-yl
  2,2,3,3-tetramethylcyclopropyl
AM-1248   adamantan-1-yl[1-[(1-methylpiperidin-2-yl)
methyl]-1H-indol-3-yl]methanone
  1-methylpiperidin-
2-yl methyl
  adamantan-1-yl
FUB-144   [1-(4-fluorophenyl)methyl-1H-indol-3-yl]
(2,2,3,3-tetramethylcyclopropyl)methanone
  (4-fluorophenyl)
methyl
  2,2,3,3-tetramethylcyclopropyl
UR-144   (1-pentyl-1H-indol-3-yl)
(2,2,3,3-tetramethylcyclopropyl)methanone
  pentyl   2,2,3,3-tetramethylcyclopropyl
XLR-11 (5F-UR-144)   [1-(5-fluoropentyl)-1H-indol-3-yl]
(2,2,3,3-tetramethylcyclopropyl)methanone
  5-fluoropentyl   2,2,3,3-tetramethylcyclopropyl
XLR-12   2,2,3,3-tetramethylcyclopropyl[1-(4,4,4-
trifluorobutyl)-1H-indol-3-yl]methanone
  4,4,4-trifluorobutyl   2,2,3,3-tetramethylcyclopropyl
Table 6: Indole carboxylates.
O
N
R1
O
R2
Common name  Chemical name   R1   R2
5F-PB-22   quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-
carboxylate
  5-fluoropentyl   quinolin-8-yl
BB-22 
(QUCHIC)
  quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-
3-carboxylate
  cyclohexylmethyl   quinolin-8-yl
FDU-PB-22   naphthalen-1-yl 1-[(4-fluorophenyl)methyl]-
1H-indole-3-carboxylate
  (4-fluorophenyl)
methyl
  naphthalen-
1-yl
FUB-PB-22   quinolin-8-yl 1-[(4-fluorophenyl)methyl]-1H-
indole-3-carboxylate
  (4-fluorophenyl)
methyl
  quinolin-8-yl
NM-2201 
(CBL-2201)
  naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-
3-carboxylate
  5-fluoropentyl   naphthalen-
1-yl
PB-22 (QUPIC)   quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate  pentyl   quinolin-8-yl
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and one compound may be referred to by different names; for example, ADB-CHMINACA is also termed 
MAB-CHMINACA. Along with changes in the chemical structures of SCs and naming conventions came 
an ever-increasing degree of potency with respect to the new classes’ ability to bind to and activate the 
cannabinoid receptors [14].
Table 7: Indole carboxamides.
O
N
R1
HN
R2
Common name   Chemical name   R1   R2
5F-CUMYL-PICA   1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indole-3-
carboxamide
  5-fluoropentyl   2-phenylpropan-2-yl
5F-NNEI (5F-
MN24)
  1-(5-fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-
carboxamide
  5-fluoropentyl   naphthalen-1-yl
AB-BICA   N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-benzyl-1H-
indole-3-carboxamide
  benzyl   1-amino-3-methyl-1-
oxobutan-2-yl
AB-CHMICA   N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
(cyclohexylmethyl)-1H-indole-3-carboxamide
  cyclohexylmethyl   1-amino-3-methyl-1-
oxobutan-2-yl
AB-FUBICA   N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-[(4-
fluorophenyl)methyl]-1H-indole-3-carboxamide
  (4-fluorophenyl)
methyl
  1-amino-3-methyl-1-
oxobutan-2-yl
ADBICA   N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
indole-3-carboxamide
  pentyl   1-amino-3,3-dimethyl-
1-oxobutan-2-yl
ADB-BICA   N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-benzyl-1H-
indole-3-carboxamide
  benzyl   1-amino-3,3-dimethyl-
1-oxobutan-2-yl
ADB-FUBICA   N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl-1)-[(4-
fluorophenyl)methyl]-1H-indole-3-carboxamide
  (4-fluorophenyl)
methyl
  1-amino-3,3-dimethyl-
1-oxobutan-2-yl
CUMYL-BICA   1-butyl-N-(2-phenylpropan-2-yl)-1H-indole-3-
carboxamide
  butyl   2-phenylpropan-2-yl
CUMYL-PICA   1-pentyl-N-(2-phenylpropan-2-yl)-1H-indole-3-
carboxamide
  pentyl   2-phenylpropan-2-yl
5F-SDB-006   N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide   5-fluoropentyl   benzyl
MDMB-CHMICA 
(MMB-
CHMINACA)
  methyl (2S)-2-[1-(cyclohexylmethyl)-1H-indole-3-
carboxamido]-3,3-dimethylbutanoate
  cyclohexylmethyl   methyl 
3,3-dimethylbutanoate 
(2S substituted)
MDMB-FUBICA   (2S)-2-[1-(4-fluorophenyl)methyl]-1H-indole-3-
carboxamido-3,3-dimethylbutanoate
  (4-fluorophenyl)
methyl
  methyl 
3,3-dimethylbutanoate 
(2S substituted)
MMB-2201   methyl [1-(5-fluoropentyl)-1H-indole-3-carbonyl]-L-
valinate
  5-fluoropentyl   methyl L-valinate 
(N-substituted)
MMB-FUBICA   methyl N-{1-[(4-fluorophenyl)methyl]-1H-indole-3-
carbonyl}-L-valinate
  (4-fluorophenyl)
methyl
  methyl L-valinate 
(N-substituted)
NNEI (MN24)   N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide   pentyl   naphthalen-1-yl
PX-1 (5F-APP-
PICA; SRF-30)
  N-(1-amino-1-oxo-3-phenylpropan-2-yl)-[1-(5-
fluoropentyl)-1H-indole]-3-carboxamide
  5-fluoropentyl   1-amino-1-oxo-3-
phenylpropan-2-yl
SDB-001 
(APICA; 2-NEI)
  N-(adamantan-1-yl)-1-pentyl-1H-indole-3-carboxamide   pentyl   adamantan-1-yl
SDB-006   N-benzyl-1-pentyl-1H-indole-3-carboxamide   pentyl   benzyl
STS-135   N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-
carboxamide
  5-fluoropentyl   adamantan-1-yl
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3   Synthetic cannabinoids classification
Delineated in Tables 1–8 are the common and IUPAC names as well as the chemical structures of a number of 
SCs. The substances listed in the Tables are representative compounds of the associated chemical subclass and 
were selected because they were reported in the scientific literature or have been identified as recreational drugs.
The cyclohexylphenol cannabinoids (Table 1) are bicyclic derivatives of classical cannabinoids, such as 
Δ9-THC. The aliphatic side chain has been the most widely modified moiety, spanning from 6 to 9 carbon 
atoms in length.
Naphthoylindoles (Table 2) represent the prototypical “first generation” SCs and were identified in many 
herbal products. The effect of substituting at position R1 on the naphthyl moiety has been investigated by 
replacing the H-atom with an alkyl or methoxy substituent. The indole core has also undergone extensive 
chemical manipulation, specifically at the R2 position, including the addition of varying length alkyl chains 
and halogenated alkyl chains, and the introduction of rings including piperidine, azepane and morpholine.
Newer compounds identified were the result of modifying the molecule by replacing the naphthoyl 
moiety with a number of aromatic (benzoyl, Table 3; phenylacetyl, Table 4) and non-aromatic (alkoyl, Table 
5; carboxylate, Table 6; carboxamide, Table 7) groups, creating multiple analogues with various substitu-
tions. Furthermore, heteroaromatic core groups have recently substituted the indole core, the most prevalent 
being indazole (Table 8).
This denotes the near-endless possibilities for developing cannabimimetic NPS, and poses the challenge 
of monitoring chemical, pharmacological, forensic, and regulative aspects of such a heterogeneous class of 
compounds.
Other indole-type SCs not described in the above tables include: piperazoyl indoles (e.g. MEPIRAPIM), 
thiazolyl indoles (e.g. PTI-1), and naphthylmethyl indoles (e.g. JWH-175). Less common compound classes have 
also emerged, such as those illustrated in Fig. 3. It is expected that such classification will expand to additional 
chemical subclasses as chemists continuously exploit chemical versatility in designing new analogues.
4   Cannabinoid mechanisms and effects
Psychoactive drugs are often weak acids or bases that are lipophilic and are able to cross the blood-brain 
barrier (BBB). They interact with the brain’s neurotransmitter systems and thus modify the normal network-
ing between the approximately 85 billion cerebral nerve cells.
4.1   Chemical synapses
A nerve cell (neuron) consists of a cell body and two types of protrusions: branched, short extensions (den-
drites) receiving excitatory signals from neighboring cells, and a single long axon which propagates the 
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Fig. 3: General structures of emerging classes of synthetic cannabinoids.
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resulting excitatory impulse over a distance. The transmission of excitatory impulses from one neuron to 
another occurs mainly at narrow (about 15 to 30 nm) clefts between adjacent nerve terminals, the chemical 
synapses [38, 39]. When an excitation wave arrives at the presynaptic terminal, neurotransmitter molecules 
are released, diffuse across the synaptic cleft, bind to their receptor at the postsynaptic membrane, induce a 
change of membrane potential, and thus propagate (or in some instances inhibit) the excitation in the post-
synaptic neuron.
4.2   Cannabinoid receptors and endocannabinoids
Endocannabinoids (EC) are the natural neurotransmitters (NT) of the cannabinoid system [40–42]. The prin-
cipal representatives are arachidonolyethanolamine (AEA, anandamide) and 2-arachidonoylglycerol (2-AG) 
[43]. These lipid mediators are biochemically synthesized from the polyunsaturated fatty acids of the post-
synaptic membrane (most notably arachidonic acid).
In comparison to other neurotransmitter systems, the EC system has several peculiar features (Fig. 4). 
First, it acts in a retrograde manner [44], meaning that EC are released from the postsynaptic cell termi-
nal and travel “backwards” across the synaptic cleft to the presynaptic membrane, where CB receptors are 
located. Second, EC do not act as the principal neurotransmitters of a synapse, but instead modulate (usually 
inhibit) the release of the principal neurotransmitter (e.g. GABA, glutamate, and others) of that synapse. The 
transmembrane receptor is coupled to a G-protein. Cannabinoid binding to the receptor induces a guanosine-
triphosphate- (GTP-) dependent signal that then modulates intracellular cyclic-adenosine monophosphate 
(c-AMP) levels, which change transmembrane ion fluxes, resulting in the partial inhibition of presynaptic 
neurotransmitter release. Thereafter, the endocannabinoid molecule is either removed by a putative reuptake 
Fig. 4: Endocannabinoid pathways (blue) and drug interactions (red) in the synapse. EC, such as AEA, are formed in the 
postsynaptic terminal from membrane phospholipids (Step 1) and released “retrograde” into the synaptic cleft (Step 2). They 
are then bound to one of the cannabinoid receptors on the presynaptic membrane (Step 3). This activates intracellular signal-
ing pathways, involving Gi (inhibitory G-protein) and cyclic-adenosine monophosphate (c-AMP), and modifies ion channels (K+, 
Ca++). Finally, the release of the principal NT from the presynaptic membrane is attenuated (Step 4). The inactivation of EC in the 
synaptic cleft (Steps 5–6) proceeds by either the enzyme fatty acid amide hydrolase (FAAH, cleaves AEA) or the monoacylglyc-
erol lipase (MAGL, cleaves 2-AG), or by reuptake into a cell. Also shown are the targets of cannabinoid agonists (e.g. JWH 018), 
antagonists (e.g. Rimonabant), cannabinoid reuptake inhibitors (CBRI), and FAAH inhibitors.
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transporter back into the postsynaptic terminal or it is enzymatically degraded and thus inactivated. AEA 
is degraded by fatty acid amide hydrolase (FAAH) enzymes and 2-AG by monoacylglycerol lipase (MAGL) 
[45, 46].
SCs compete with endogenous endocannabinoids at CB receptor sites. The prevailing receptors are CB1 
and CB2 [47]; however, a number of additional receptors, such as the transient receptor potential vanilloid 
type 1 (TRPV1) and G protein-coupled receptor 55 (GPR55), exist. The CB1 receptor is strongly expressed in the 
brain and is responsible for the psychotropic effects of marijuana; CB2 is a peripheral receptor expressed in 
the immune system, the brain, and in gastrointestinal and other organ systems. TRPV1 is located in the free 
nerve endings of pain receptors and involved in pain perception [48]. GPR55 has a role in energy metabolism. 
Increasingly, one or more of these cannabinoid receptors have been identified in other organ systems, includ-
ing the cardiovascular, reproductive, and respiratory systems. In the endogenous system, AEA is a main 
ligand of CB1, whereas 2-AG is a principal ligand of CB2 [43]. It is recognized that the affinity of a cannabinoid 
to a specific CB receptor type is related to the strength and pattern of the effect. Due to the complexity of these 
interactions, it is difficult to identify the principal target of a cannabinoid and to predict the clinical effects.
4.3   Cannabinoid effects in humans
CB1 receptors are the most abundant G protein-coupled receptors in the mammalian brain. They occur at two 
types of synapses, GABAergic synapses, which are inhibitory, and glutamatergic synapses, which are excita-
tory. The activation of one or the other receptor populations may conceivably evoke different effects [49]. Alto-
gether, the endocannabinoid system is involved in psychotropic and somatic signaling, mood-modulation, 
memory-storage, pain-sensation, and appetite. In humans, common acute effects experienced by recrea-
tional consumers of cannabis plant products include: an elevated mood and/or feeling disinhibited, relaxed, 
sociable, and euphoric, in combination with enhanced sensation of vision, sounds, and odors. Altered per-
ceptions of time and space are also common. Unpleasant effects include dizziness, impaired memory, and 
reduced coordination. Anxiety may also occur [14, 50]. Somatic signs include increased heart rate, dilated 
pupils, and red eyes.
SCs might be expected to exhibit effects similar to cannabis plant products; however, there are differ-
ences. While SC products tend to have one or several active ingredients, cannabis plant products contain 
approximately one hundred known phytocannabinoid substances, each interacting with one or more types 
of cannabinoid and other receptors, with some being agonistic, others being antagonistic or possibly exhibit-
ing additional effects [51]. The major components, Δ9-THC and cannabidiol, differ in their pharmacological 
activities, the former having pronounced psychoactive efficiency and the latter acting as an anxiolytic and 
exhibiting anti-inflammatory effects. Compared to plant cannabis, SCs are more often involved in acute and 
sometimes fatal intoxications [52, 53]. Substance-specific differences may be caused by a higher or more 
selective agonistic/antagonistic affinity of SCs to cannabinoid receptors, resulting in modulations and dis-
turbances of the neurotransmitter equilibrium in the brain [54]. Other possible causes are longer biological 
half-life or interaction with other functions of the brain. Moreover, when a drug is clandestinely synthesized 
and marketed in the absence of chemical and pharmacological control, the risks associated with overdoses, 
contamination (synthetic by-products), and blending with contraindicated agents increase.
Individuals intoxicated with SCs are commonly presented to emergency units with a range of life-threat-
ening psychiatric and somatic symptoms [14]. Some adverse effects experienced by SC consumers include, 
but are not limited to, tachycardia, anxiety, hallucinations, suicidal thoughts, acute kidney injury and hepa-
totoxicity, convulsions, psychosis, and death [14, 55]. Studies revealed that some SCs induced chromosomal 
damage in in vitro studies [56, 57], suggesting a tumor risk in chronic consumers. Cannabinoid-specific thera-
peutic tools are not available for the clinical management of patients, which instead relies on reducing the 
severe symptoms of an individual [58].
A number of severe toxic effects and deaths have been experienced by consumers of SC-containing prod-
ucts on a large scale over the past few years. Several mass intoxications were reported between late 2013 
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and early 2015 in the United States. A large outbreak occurred in 2013 in Denver, Colorado, when more than 
220 individuals were exposed to ADB-PINACA after smoking herbal blends; approximately 70 individuals 
reported to emergency departments [59, 60]. In Europe, MDMB-CHMICA was linked to 71  serious adverse 
events, 29 of which resulted in death; individuals in 8 countries were affected [61]. Multiple outbreaks also 
took place in Russia in 2015, resulting in 15 deaths and 600 hospitalizations; these incidents were attributed 
to MDMB-FUBINACA [62]. More recently, a series of 33 intoxications related to AMB-FUBINACA (MMB-FUBI-
NACA) occurred in a New York City neighborhood in the United States [36]; these exposures were unique in 
that they all occurred within a one-block radius.
In many instances, no specific drug can be identified as the root cause of a drug consumer’s adverse 
effects; this is sometimes due to the testing laboratory’s limited analytical capabilities (e.g. lack of refer-
ence material or databases), especially with regard to novel synthetic drugs, or to the short half-life of the 
substance(s) of interest. Another factor in determining the causative agent is inaccuracy in the details pro-
vided by the patient (e.g. material consumed). Some patient reports are likely to be flawed and symptoms may 
be attributable to a non-SC substance. In other instances, multi-agent exposures occur in which the effects 
experienced by drug users cannot be linked to a single compound, especially when multiple drugs exhibit 
similar effects [63].
There is some concern about unwanted developmental effects. Endocannabinoids have a role in the 
development of the neuronal system [64]; there is some evidence that prenatal cannabinoid exposure might 
influence the mental health of the child [65] and that cannabis exposure in adolescence might be associated 
with later psychiatric problems [51, 66].
Reward experiments, such as self-administration of addictive drugs by laboratory animals [67], suggest 
that dependency phenomena originate in the midbrain pathway that connects brain areas involved in 
“reward” anticipation and emotion. The brain adapts in a way such that increased cannabinoid levels are 
recognized as “normal”, possibly mediated by a reduction of CB receptor density, feedback inhibition, or 
other mechanisms of neuronal plasticity. Symptoms of withdrawal from SCs include agitation, irritability, 
anxiety, and mood changes [68]. At the present time, no specific therapeutic approaches to reduce with-
drawal symptoms are available.
Though historically banned, many countries have recently taken measures to make natural cannabis 
products available for patients to relieve symptoms of various diseases [69]. At the same time, the search for 
more specifically-acting, therapeutically useful SCs continues. Among the new developments are synthetic 
agonists and antagonists that selectively bind to the various cannabinoid receptor types; at the same time, 
agents that interact with endocannabinoid synthesis, reuptake, and degradation are also being developed 
[45]. There is evidence that such new drugs may become useful in the treatment of pain and neuro-psychiatric 
disorders. Substances that interact specifically with CB2, but not with CB1, are expected to be therapeuti-
cally useful without being psychoactive [14]. The goal is that such new pharmaceuticals, designed to opti-
mize parameters such as receptor-specificity, target organ, and half-life, may bring therapeutic advantages 
in various disorders, such as cancer, epilepsy, traumatic brain injury, glaucoma, diabetes, digestive disease, 
and immunological disorders [69], without exhibiting unwanted effects.
4.4   Tests for pharmacological spectrum
A hierarchy of assays allows researchers to determine whether a substance has cannabimimetic properties 
[70]. A common procedure is to measure the binding affinity (Ki) of a SC for a specific receptor; this involves 
the incubation of isolated CB1 and/or CB2 receptors with a predetermined fixed concentration of radiola-
beled cannabinoid ([3H] CP 55,490) [71]. The compound of interest is then added at increasing concentra-
tions and allowed to compete with the radioligand for binding. As the concentration of unlabeled ligand 
is increased, the amount of radioligand that binds to the receptor decreases, allowing one to estimate 
the binding affinity once the inhibitory concentration (the concentration of unlabeled ligand necessary 
to displace 50 % of the radioligand) is determined using the Cheng-Prusoff equation [72]. A small Ki value 
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represents a stronger receptor binding affinity, while a larger Ki represents a weaker affinity of an analyte 
for a receptor.
In most SC studies, binding affinity is determined relative to Δ9-THC; for example, Δ9-THC at CB1, Ki: 41 nM; 
JWH-018 at CB1, Ki: 9.0 nM, demonstrating that JWH-018 binds more strongly to this receptor. Such Ki values 
may differ depending on the animal or human receptor model used. This type of assay does not allow one 
to decide whether a substance is an agonist or antagonist; therefore, supplementary tests are required [14]. 
Only agonists would be expected to activate the G-protein-mediated signaling pathway. An early step of this 
pathway can be studied employing radiolabeled GTP and a subsequent step can be assessed with additional 
methods, such as a calcium mobilization test [73]. Electrophysiological studies on brain slices and cultured 
neurons elucidate effects on the excitation-propagation level [74]. The measurement of neurotransmitter 
levels in brain dialysate of rodents helps to identify effects in the whole brain [75]. Thus, dopamine elevation 
in the brain’s nucleus accumbens region suggest that the “reward” system is involved [76, 77]. Radiosynthesis 
of cannabinoid analogues for PET-imaging has also been conducted [78]. Finally, the mouse tetrad-test is an 
established system to investigate cannabinoid-characteristic effects in the mouse. It includes induced hypo-
thermia, reduced motor activity, decreased reaction to pain stimuli, and catalepsy [79]. Additionally, it has 
been reported that Δ9-THC and JWH-018 induce seizures by acting through the CB1 receptor in mice, recorded 
by electroencephalography and videography [80]. The disappearance of cannabinoid-associated effects 
upon concomitant administration of a CB-receptor antagonist would suggest a cannabinoid-specific effect. 
Though these assays are helpful to classify a suspected substance as a cannabinoid, they usually do not 
provide information about additional substance-specific effects via interaction with other receptor systems.
4.5   Structure-activity relationships (SAR) of synthetic cannabinoids
Membrane receptors are proteins stretching across the cell membrane with a ligand-binding site on the extra-
cellular surface. Depending on receptor type, ligand binding induces either the opening of an ion channel 
or an intracellular signaling cascade. The specificity of a neurotransmitter for its receptor is dictated by the 
tertiary structure of the binding pocket, its size, and lipophilic and hydrophilic environments. While endog-
enous neurotransmitters and NPS may behave similarly on the receptor-level, there are also differences. 
Endogenous neurotransmitters are released on neuronal demand, confined to the small synaptic space, as 
part of a coordinated neuronal network [81]. In contrast, SCs may bypass such temporal and spatial barriers.
After the detection of a cannabinoid receptor was reported in 1990, the search for synthetic substances 
that interact with the receptor began and additional cannabinoid receptors were identified [82]. Initially, 
compounds similar in their fundamental structure to Δ9-THC were studied [47]. Later, new classes of synthetic 
compounds were investigated [83]. The comparison of receptor binding characteristics and pharmacological 
effects provided SAR information for classical cannabinoids [47] and SCs, the latter of which often exhibited 
stronger pharmacological effects [83].
Apart from the described competitive binding, allosteric binding to the receptor [84] may induce con-
formational changes of the receptor, resulting in the modulation of the downstream signal pathway. Recent 
advances in defining the crystal structure of CB1 will help to further elucidate these SAR [85, 86].
An example of some aspects of SAR for indole-based SCs that have been thoroughly reported [87] is pre-
sented here. The basic structure, naphthoyl indole, and the relevant residue positions are shown in Fig. 5. 
Earlier studies established intriguing SAR features [88–90]; a group larger than methyl at position 2 (R1) of the 
indole moiety significantly decreased potency (unsubstituted analogues are slightly more potent than their 
methylated counterparts) and a bicyclic aroyl group (e.g. naphthoyl) at position 3 was essential for potency. 
Moreover, extensive synthetic procedures with parallel biological evaluation led to the conclusion that an 
aminoalkyl group attached to the indole ring at the nitrogen position was not essential for CB activity. This 
led to the exploration of a set of indole side chains at positions R and R1, including alkyl (particularly pentyl) 
and fluoroalkyl [91–93]. The fluoroalkyl version of JWH-018, synthetic cannabinoid AM-2201, was evaluated 
and determined to be more potent than JWH-018, demonstrating the impact of the presence of fluorine on 
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binding affinity [94]. Optimal affinity for CB1 receptors was found in the presence of an n-pentyl group as the 
R group (Fig. 5), the potency decreasing with shorter (3 or less carbons long) or longer (6 or longer carbons 
long) chains. The exchange of the naphthoyl-group for a 4-methoxy-1-naphthoyl group at position 3 of the 
indole ring increased the CB1 receptor affinity; however, the 4-ethoxy derivatives were less potent.
Moderate or very low affinity was observed in the 1-alkyl-3-(2-methoxy-1-naphthoyl) analogues, suggest-
ing that a substitution at position 2 of the naphthoyl moiety is less likely to induce strong receptor binding 
[87]. Similar considerations exist for the 6-methoxy-substitution on the naphthoyl ring, the only exception 
being the 6-methoxy-derivatives bearing a n-pentyl chain on the indole ring, which still preserve a good 
affinity for CB1 [87]. The introduction of a methyl group in position 7 of the naphthoyl ring did not appear to 
perturb the affinity towards both CB1 and CB2 receptors, whereas a decrease in affinity for both CB receptors 
was observed for the 7-ethyl-1-naphthoyl derivatives. The 7-methoxy-1-naphthoyl series did not retain good 
affinity for either receptor [87]. A study directed towards the development of CB2-selective agonists high-
lighted the fact that the substitution of the n-pentyl group in the indole-side chain with an n-propyl group 
was essential for increasing the CB2/CB1 affinity ratio. A high ratio demonstrates an analyte’s preference for 
the CB1 receptor and a higher potential for recreational use. As previously described, the n-pentyl substitution 
at position R of the indole ring is the lead side-chain for high CB1 affinity. It is thus not surprising that most 
SCs on the market contain either an n-pentyl or a 5-fluoropentyl substitution to maximize their psychoactive 
effects. 4-Alkyl-1-naphthoyl analogues generally increase CB1 and CB2 affinities up to a propyl chain, while 
butyl analogues disrupt such an effect.
SAR investigations provide invaluable information to forensic toxicologists wishing to evaluate bioas-
says for NPS or for cannabinoid researchers interested in designing new relevant analogues [95, 96]. Most of 
these compounds do not progress in pre-clinical or clinical research due to their psychoactivity or toxicity; on 
the other hand, clandestine drug manufacturers frequently evaluate these compounds to identify potential 
candidates for sale and distribution for recreational purposes. Besides the naphthoylindoles SC class, SAR 
studies have been reported on other classes, including valinate and tert-leucinate SCs, and indole and inda-
zole carboxamide SCs [97–99].
5   Metabolism of synthetic cannabinoids
The metabolism of ingested drugs generally proceeds in two enzymatic steps, known as Phase I and Phase 
II. In Phase I biotransformation, the drug molecule undergoes structural modifications, commonly via oxi-
dation, resulting in a hydroxylated or carboxylated metabolite. In the subsequent Phase II, the oxidized 
molecule is often conjugated with glucuronic acid or sulfate, generally at the site of the newly introduced 
hydroxyl or carboxyl groups. The resulting conjugates are more water soluble, usually exhibit reduced or 
Fig. 5: Generic structure of indole-based synthetic cannabinoids (adapted from [87]).
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negligible pharmacological activity, and are readily eliminated via urine or bile. The liver has the highest 
drug- metabolizing activity [100], but some activity is also present in other organs, notably the intestine, 
kidney, and lung [15].
Most SC metabolism studies have been conducted via in vitro human liver microsome (HLM) or via 
human hepatocyte incubations [15]. HLM are rich in drug-metabolizing enzymes of the liver, such as Phase 
I Cytochrome P450 (CYP450) enzymes, carboxylesterase (CES) enzymes, and Phase II UDP-glucuronosyl-
transferase (UGT) enzymes. There are, in general, inter-individual variations in the presence and activity of 
human liver enzymes in vivo; in laboratory experiments, this issue is overcome through the use of pooled 
HLM, which are typically composed of material from 50 or more donors [101]. While HLM are an effective 
matrix for metabolism determination studies, human hepatocytes are superior to HLM, allowing for a better 
simulation of the human liver environment. Some hepatocyte studies were accompanied by HLM incuba-
tion to determine metabolic clearance of the analytes of interest, as well as the application of the method 
to authentic human urine samples for the determination of the most appropriate biomarkers for analytical 
drug screening [102–105].
Metabolite prediction software, including MetabolitePilot™, MetaboLynx™ and MetaSite™, has been 
used in metabolism determination studies to facilitate the identification of expected metabolites. While some 
functions differ between programs, there are many similarities. Some features of the software include enter-
ing the structure of the parent compound of interest and pre-selecting the most probable biotransformation 
sites on the molecule to facilitate metabolite elucidation. CYP enzyme activity at various sites on the sub-
strate molecule and expected metabolites formed in various human tissues, i.e. liver, brain, lungs, and skin, 
is taken into consideration [15]. A likelihood score is calculated based on metabolites tentatively identified 
during mass spectrometry analysis of incubation samples. This type of software is especially useful for data 
processing, as it helps guide researchers through the metabolite structure elucidation procedure.
In general, there are two primary Phase I metabolic pathways observed for SCs. The first is hydroxylation 
(primarily monohydroxylation) that may occur at various sites on the molecule, but predominantly along 
the aliphatic side chains. This hydroxylation is often followed by oxidation to the corresponding carboxylic 
acid [15]. Figure 6 shows the major biotransformation pathways of AB-FUBINACA and of JWH-018, including 
major hydroxylated and carboxylated metabolites and glucuronides. Care must be taken when developing 
analytical methods to identify SC metabolites; many compounds, for example XLR-11 and UR-144 (Table 5), 
share metabolites, as these two parent molecules are structurally related. XLR-11 is the fluorinated analogue 
of UR-144. Fluorinated SCs commonly undergo enzymatic defluorination during metabolism; it is crucial to 
screen for metabolites that are specific to the molecule of interest and are not shared with another SC [102, 
104]. SCs that are substituted with fluorobenzyl (e.g. AB-FUBINACA, ADB-FUBINACA, FUB-PB-22) in the core 
structure do not commonly undergo biotransformation on that site of the molecule, but on other portions of 
the molecule [108, 109].
The second major metabolic route is through hydrolysis of compounds with amide or ester functional 
groups to carboxylic acid metabolites. This process of metabolism is typically facilitated by various hydro-
lases, including CES enzymes and/or amidase enzymes [108, 110, 111]. In these specific biotransformations, 
CYP enzymes are not the primary agents involved with the production of the major metabolites. In multiple 
studies, microsome incubations were performed in the presence and absence of NADPH-regenerating solu-
tion (which activates the CYP enzymatic activity). In the reactions without NADPH, the major metabolites 
identified were carboxylated hydrolysis products; in some instances, metabolites were identified that were 
hydrolysis products that were also hydroxylated.
Hydroxylated and carboxylated metabolites often undergo subsequent metabolism via Phase II processes 
in which they are conjugated with glucuronic acid facilitated by UGT enzymes (Fig. 6). SCs are excreted in 
urine predominantly as glucuronic acid conjugates [112].
Many hydroxylated metabolites of SCs exhibit pharmacological activity, binding to and activating the CB1 
receptor to produce a greater biological effect than that of Δ9-THC. In a competition binding assay by Brents 
et al., a hydroxylated metabolite of JWH-018 produced a high binding affinity, Ki, of 2.6 nM, compared to Δ9-
THC, 15.29 nM [113, 114]. Carboxylated metabolites and glucuronic acid conjugates have also been evaluated 
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for activity, but no significant contribution to impairment can be inferred, as these molecules either do not 
bind to the receptor or act as antagonists rather than agonists [113, 114].
6   Forensic investigation of synthetic cannabinoids
6.1   Analysis of non-biological matrices
Non-biological matrices that have been analyzed for the presence of SCs include herbal blends, bulk powders, 
liquids, and capsules [9, 115]. These materials are generally submitted by law enforcement personnel and 
legal representatives to forensic laboratories for investigative purposes. Cases of interest include drug pos-
session and trafficking seizures, mass intoxication, and death investigations [36, 116, 117]. Many small-scale 
seizures (a few grams of material) take place when materials are discovered by police officers when individu-
als are stopped while driving; large-scale seizures (many kilograms) often occur when clandestine laborato-
ries are discovered, or when materials were confiscated by customs and border control agencies following 
attempts to import and export substances [14, 116, 118]. When adverse events and deaths occur, material 
Fig. 6: Chemical structures and metabolic pathways of AB-FUBINACA and JWH-018; AB-FUBINACA (1) AB-FUBINACA-COOH, (2) 
AB-FUBINACA monohydroxy (3), AB-FUBINACA-COOH glucuronide (4), AB-FUBINACA monohydroxy glucuronide (5), JWH-018 (6) 
JWH-018 N-(4-hydroxypentyl) (7), JWH-018 N-(5-hydroxypentyl) (8), JWH-018 N-pentanoic acid (9), JWH-018 N-(4-hydroxypentyl) 
glucuronide (10), JWH-018 N-(5-hydroxypentyl) glucuronide (11), JWH-018 N-pentanoic acid glucuronide (12). CES, Carboxylester-
ase; CYP, Cytochrome P450; GA, glucuronic acid; UGT, Uridine 5′-diphospho-glucuronosyltransferase. AB-FUBINACA pathway: 
see [106]; JWH-018 pathway: see [107].
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found in the possession of the individual(s) of interest is commonly collected and analyzed to determine if the 
compounds identified in the products were a contributing factor. This type of information is very important 
to death investigators and forensic toxicologists [36, 117].
Sample preparation for analysis of non-biological materials is highly dependent on the type of instrumen-
tation that will be used for identification and quantitation purposes. The most common means of qualitative 
analysis of SCs in the forensic chemistry laboratory is Gas Chromatography-Mass Spectrometry (GC-MS), while 
quantitation is typically performed using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). 
GC-MS is most commonly employed for the identification of unknown compounds. Since volatile solvents 
are needed for GC-MS analyses, the matrix (e.g. powder, plant material) is commonly dissolved or soaked in 
a solvent and sonicated, followed by liquid-liquid extraction. For molecules with certain functional groups 
(e.g. hydroxyl), derivatization is sometimes needed as a preliminary step for instrumental analysis to enhance 
the detection signal [118, 119]. LC-MS/MS analysis requires that drugs are extracted into a suitable solvent, 
followed by either a chromatographic process or direct infusion into the mass spectrometer. For the confirma-
tion and quantification of SCs, LC-MS/MS is generally used: the precursor ion is isolated and fragmented and 
product ion spectra are obtained. This provides a superior level of specificity relative to instruments with a 
single mass analyzer, e.g. GC-MS.
When elucidating the structure of an unknown SC, it is essential to use multiple analytical tools, as each 
type of instrumentation provides unique information about the molecule(s). The data from each technique 
can be combined systematically to provide complete structural information. A case study was reported for the 
evaluation of two samples seized by Belgian customs authorities, originating from China and labeled “white 
pigments”. The samples were first analyzed by GC-MS and Fourier Transform-Infrared (FT-IR) spectroscopy. 
The samples were subsequently analyzed in a specialized laboratory, where the characterization was com-
pleted. Using Nuclear Magnetic Resonance (NMR), high-resolution tandem mass-spectrometry (HR-MS/MS) 
and Raman spectrometry, the SCs 5-fluoro AMB and PX-3 (APP-CHMINACA) were identified [120].
A number of studies were performed in which the amount of SCs present in the botanical material was 
quantified; overall, these results showed that there are often large variations in the concentrations of analyte 
between packages. The ranges reported were as follows: 1.09 to 210.90 mg/g (46 products evaluated), 3.65 to 
340 mg/g (20 packages evaluated), and 1 to 120 mg/g (9 products evaluated) [62, 121, 122]. Additional studies 
on over 140 packets of herbal products revealed that some were counterfeit, containing no SCs, while others 
included substances that were not SCs, including Δ9-THC, cannabinol, nicotine, and O-desmethyltramadol. 
Additionally, identically-named packages purchased weeks apart contained different substances [123]. 
Results such as these demonstrate the lack of consistency in the contents of these products, the absence of 
quality control, and the inherent risk involved with consuming these materials.
6.2   Analysis of biological matrices
The ability to detect and quantify SCs in biological samples is essential in both clinical and forensic toxicol-
ogy. Analyses in these fields include testing samples collected from patients in hospitals after intoxication 
events; workplace, sports doping, probation, and parole drug testing; forensic psychiatry facilities; samples 
collected from those driving under the influence of drugs (DUID); and post-mortem evaluations. In order 
for analytical laboratories to develop methods for the analysis of SCs in biological specimens, data from 
metabolism studies and in vivo analyses must be used to evaluate the distribution and excretion profiles of 
the substances when ingested [124]. A gap still exists, however, since the metabolism profiles of many classes 
of SCs and substances identified in non-biological materials have yet to be determined. Additionally, instru-
ment sensitivity plays an important role in the development of laboratory tests, as many SCs are frequently 
present at sub-nanogram concentrations in authentic biological samples. Another challenge faced by labo-
ratories is the fact that SCs are not detected in traditional drug screens. As a result, in many instances the 
substance(s) contributing to impairment are not identified during the screening process [15]. Many laborato-
ries cannot bear the expense of purchasing parent and metabolite reference material to maintain screening 
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panels that include the most recent compounds. Detailed evaluations also include determining the typical 
range of concentrations of analytes and their metabolites in various matrices, including urine, blood, serum, 
oral fluid, hair, and tissues, depending on the purpose of the testing. Analyte stability is an important consid-
eration when developing analytical methods for SCs. Each method validation plan should contain a section 
dedicated to evaluating the short-term and long-term stability of the compounds in the matrices of interest 
under various storage conditions, e.g. room temperature, refrigerated, and frozen. The stability of SCs is vari-
able between chemical classes and matrices; many compounds are generally stable in blood and urine, but 
often experience severe matrix effects in oral fluid and tissues, which may lead to the need for standard addi-
tion for quantitation purposes [15].
A variety of sample preparation techniques have been reported for the analysis of biological samples 
containing SCs; these include liquid-liquid extraction (most common), solid phase extraction, precipitation 
reactions, and simple dilutions in mobile phase [117, 125–128].
Quantitative analysis is typically conducted via LC-MS/MS. However, the use of Ultra High Performance 
Liquid Chromatography-Tandem Mass Spectrometry (UHPLC-MS/MS) for the separation, identification, and 
quantitation of analytes of interest is becoming more prevalent. Higher throughput is more readily achievable 
using UHPLC-MS/MS with shorter run times and targeted analyses. High resolution mass analyzers includ-
ing time-of-flight (TOF) and Orbitrap devices are being used more regularly in laboratories for SCs analysis, 
particularly in determining metabolite profiles. The use of these mass analyzers is essential due to the diver-
sity of SCs and the large number of isomeric compounds that exist within this class; it is important to have 
sufficient chromatographic separation as well as detection methods to ensure proper identification [15, 102, 
117, 129]. Analyses have also been conducted via GC-MS [130, 131]. This frequently requires a derivatization 
processes that is beneficial for the separation of co-eluting or poorly-resolved isomers.
Parent SCs have not been detected in appreciable quantities in urine samples. Their metabolites, however, 
are readily detectable in urine. This is particularly useful, as urine is one of the most common matrices utilized 
for drug screening purposes. Since most SCs are excreted as conjugates in urine, β-glucuronidase is added to 
samples during the incubation phase to deconjugate the drugs prior to instrumental analysis [132, 133]. Con-
centrations of SC metabolites in urine samples were determined in many studies; in one large study, 20 000 
randomly collected urine samples were tested for various SCs. The average concentration of all analytes evalu-
ated ranged from 1 to 11 ng/mL, with a true range of 0.1 to 2434 ng/mL [134]. Studies have revealed that a 
 detection window ranging from a couple of days up to one week is achievable for certain analytes [132, 135].
The results of blood analyses provide information about the circulating drug concentrations in the body 
at the time of sample collection. This matrix is commonly used for DUID and post-mortem evaluations, when 
it is essential to know which substances were in the blood during an incident. The number of published 
studies in which blood was tested is limited and only a few describe the identification and quantitation of SC 
metabolites in blood [125, 129, 136, 137]. It is important to further investigate the presence of these metabo-
lites, as studies have shown that both SC parent and metabolite compounds can have pharmacological activ-
ity and may contribute to the overall adverse effect profile experienced by drug users [113, 114]. The presence 
of metabolites may also extend the detection window, since the parent compound is rapidly eliminated from 
the blood [136].
Several authors have reported quantitative analyses of SC parent compounds in blood; these methods typ-
ically have limits of detection (LOD) and limits of quantitation (LOQ) of approximately 0.1 ng/mL and 0.5 ng/
mL, respectively. Typical sample concentrations range from approximately 0.1 to 10 ng/mL, highlighting the 
need for sensitive instrumentation. Some postmortem samples were much higher, 68 to 200 ng/mL, which 
may be attributed to chronic consumption or postmortem redistribution (PMR), where the sample collected 
at autopsy has an unusually high concentration, dissimilar to what would have been commonly detected in 
a sample collected from a living individual [16, 129, 136]. A study was performed to determine the absorption 
profile of JWH-018 and JWH-073 in which an individual smoked an herbal product containing the two sub-
stances, while blood samples were collected over a period of approximately 3 hours [136]. Peak concentrations 
of both compounds in blood were observed after 19  minutes, at 4.8 and 4.2 ng/mL for JWH-018 and JWH-
073, respectively. The concentrations decreased to less than half after 53 minutes, 1.5 and 1.0 ng/mL, and by 
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199 minutes the concentrations had both decreased to 0.2 ng/mL, demonstrating that the half-life of JWH-018 
and JWH-073 in blood is very short. In order to obtain positive results for this matrix, the blood must be drawn 
at a time very close to the moment the material containing these compounds was ingested by the subject.
A study that complements this data was performed, in which over 600 blood samples were screened for 
the presence of JWH-018 and one hydroxylated (JWH-018 N-(5-hydroxypentyl)) and one carboxylated metabo-
lite (JWH-018 N-pentanoic acid) via UHPLC-MS/MS [129]. JWH-018 was identified in only 3 of the 600 samples 
at a concentration range of 0.3 to 0.8 ng/mL; JWH-018 N-(5-hydroxypentyl) was detected in 92 samples (con-
centration range: 0.3 to 22.7 ng/mL), while JWH-018 N-pentanoic acid was detected in 145 samples (concen-
tration range: 0.3 to 63.5 ng/mL). In the study performed by Kacinko et al. [136], the parent concentration 
dropped rapidly after a short period of time. In this study, parent compound was present in less than 1 % of 
samples, while metabolites were present in more samples and at higher concentrations. This is especially 
significant, since the hydroxylated metabolite in this study was identified as a CB1 receptor agonist by Brents 
et al. [114].
While urine and blood are the most commonly analyzed matrices, hair and tissues are also relevant 
specimens. Hair is analyzed to determine historical drug use in consumers, while tissue samples are analyzed 
post-mortem and reveal substances consumed prior to death. One of the main challenges that arise when 
analyzing hair is the interpretation of results; it is essential to ensure true positives by screening for not only 
parent compounds, but also metabolites, as passive exposure to SCs contained in smoke has been reported 
to cause false positives [138–140]. Studies have also demonstrated that, for certain compounds, smoke con-
densates contain known metabolites of the parent compound of interest [141]. This often results from the 
production of external degradation products formed by hydrolysis of amide and ester bonds. Tissue samples, 
including adipose tissue, brain, heart, skeletal muscle, kidney, liver, pancreas, and spleen, have been tested 
for SCs in post-mortem evaluations; these types of analyses are commonly conducted in parallel with urine 
and blood samples and provide medical examiners and forensic toxicologists with information regarding the 
distribution of drugs throughout the body around the time of death [117, 142].
7   Regulation
7.1   Monitoring
Effective drug regulation and administration does not prohibit substances only, but also monitors drug emer-
gence and intoxication trends and offers solutions to public health issues that arise. This requires a sentinel 
system that actively collects data on relevant parameters, such as the number of drug seizures, identity and 
concentration of the psychoactive substances in seized products, number and severity of medical emergen-
cies, and other factors. This requires the cooperation of a network of individuals, including medical experts, 
toxicology center personnel, forensic institutes, analytical scientists, law enforcement officials, and legis-
lators. These individuals must work collaboratively to alert agencies at all levels (local, state and federal) 
regarding emerging NPS, prevalence trends, and potential public health threats. All of the relevant informa-
tion must be documented, compiled, and evaluated; this work must be coordinated and supervised by a 
responsible agency in each jurisdiction.
7.2   General aspects
Public health and consumer safety are of the highest priority in drug regulation; any newly developed phar-
maceutical drug must undergo scrutinized safety investigations before it can be considered a candidate for 
human application. These evaluations include, but are not limited to, pharmacokinetic, pharmacodynamic, 
and toxicological studies.
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Most recreational NPS have not been evaluated in humans due to ethical and regulatory restrictions. 
They are typically lipophilic substances, able to cross the BBB, exert a multitude of neuronal interactions 
with dangerous psychoactive outcomes, and altogether provide an extraordinarily high risk for involved indi-
viduals and the overall public health. Information such as chemical synthesis, as well as pharmacologi-
cal and/or undesired effects, are often shared online through fora where users exchange methods, doses to 
produce a “high”, and promote various NPS products, thus augmenting the popularity of these drugs. Users 
are attracted by the ambiguous legal status associated with NPS, the low cost of these substances relative 
to conventional recreational drugs (e.g. cocaine, MDMA), and the lack of detection by routine drug screens.
The present legal situation is very complex. Marijuana has been recognized for its medicinal proper-
ties for thousands of years [47] and is becoming legalized in many countries; this trend is paralleled by the 
development of cannabimimetic pharmaceuticals for novel therapies. Alternatively, recreational SCs are pro-
hibited, as they have no accepted medical use, present a high abuse potential, and exhibit a threat to public 
safety [9]. In general, however, when governments take action to prohibit individual SCs, illegal manufac-
turers remove the banned substances from their products and replace them with new compounds that are 
not included on the list of prohibited substances, making it very difficult for government agencies to control 
them [143].
7.3   Making “legal highs” illegal
Regulatory measures need to be updated frequently as a result of the ongoing changes in the recreational 
drug use landscape [144]. Some of these approaches have been summarized for the United States, many 
European countries, regions of Asia, and Australia [9, 14, 15, 145, 146]. Initially, only a few SC substances were 
controlled; subsequently, the scope was repeatedly expanded to include new drugs of abuse. Regulatory 
decision-making processes may differ between countries, though the rationale is often similar.
One approach to banning NPS is to list substances by name in drug legislation. If they are listed, it may be 
easier to identify them and understand their legal status; however, if substances are not listed by name, then 
they are not considered illegal [9]. In addition to their chemical name, it is recommended that their common 
or generic name (e.g. JWH-018) is also listed in order to facilitate the identification process. The use of Inter-
national Chemical Identifier (InChI™) keys [147, 148] as a digital tool for unambiguous drug identification in 
databases may be beneficial for implementation into legislation in the future.
Another approach follows the “analogue” principle, which varies from country to country. For example, 
in 2012, the United States Congress decided to schedule a number of SC drugs and entire classes of their 
chemical analogues [9]. According to this legislation, individuals can be prosecuted for the manufacture, 
sale, possession, importation, and/or exportation of these compounds. Under the “analogue” principle, sub-
stances with a “substantially similar” chemical scaffold and pharmacological activity could be regulated 
in a manner similar to the known psychoactive prototype. However, there are numerous concerns about 
the concept for several reasons [9, 149]. First, there is no overall consensus in the field around the limits 
of an “analogue” (number, size, and composition of substituents). Second, it is not always clear whether 
“analogue” refers only to the chemical structure or also to the pharmacological, toxicological, and addictive 
effect. Additionally, the requirement of “substantially similar” pharmacological activity would presume that 
pharmacological data on a newly detected substance is available; however, for SCs this is often not the case.
Several different approaches to define analogues have been taken by lawmakers in Australia, including 
outlining the allowable molecular modifications to a controlled substance (e.g. number and type of addi-
tions/replacements of moieties) that make it an analogue. This legislation excludes references to pharmaco-
logical activity in an attempt to simplify the analogue definition. Similar to the United States, Australia also 
includes in legislation a reference to structural similarity between the controlled substance and the molecule 
(NPS) in question. The opinion of an expert is also considered in legal proceedings pertaining to similarity. A 
survey of 40 experienced scientific researchers was conducted and those polled were presented with chemi-
cal structures of 6 pairs of molecules sharing some structural features. They were asked whether or not the 
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molecules were similar in structure and were also provided a short excerpt from legislation related to struc-
tural similarity. The results showed that overall there was no definitive agreement amongst the scientists as 
to whether or not the compounds in question were structurally similar. These findings demonstrate some of 
the challenges involved with an expert’s responsibility to determine whether or not an NPS can be classified 
as an analogue of an existing controlled substance, as structural similarity is a component of most analogue 
laws. Some experts surveyed commented that consideration must also be given to the functional groups of 
the molecules and the 3-dimensional arrangement of the compounds. The legal system is challenged with 
making decisions based on the opinions provided by scientists who are experienced in their field, but who 
may not agree with other experts in this area. Of equal importance is the fact that, while the structures of two 
substances may be similar, it does not necessarily equate to similar pharmacological activity [146].
Similar problems arise when regulation is based on the “pharmacophore rule” [150]. In the United 
Kingdom, a “blanket ban” approach was implemented in 2016, controlling any substance able to produce 
a psychoactive effect (with the exception of common substances including caffeine, nicotine, and alcohol) 
[151]. Medicinal chemists are concerned that the application of the analogue principle or blanket ban may 
result in an overloaded “catch all” philosophy, which would hamper the development of CB receptor ligands 
for therapeutic purposes. In the future, a new approach to controlling drugs may make use of SAR to predict 
potential effects on humans [152].
In Japan, three SCs, including JWH-018, were listed as “Designated Substances” under the Pharmaceuti-
cal Affairs Law in 2009. A “Designated Substance” classification is used as a measure to more strictly control 
NPS. Over the years, many SCs have been listed under this law. In March 2013, a generic definition covering 
naphthoylindoles was introduced into this law, followed by the classification of 759 compounds as Desig-
nated Substances [153]. As of December 2016, 2,356 substances, including 869 SCs (110 individual scheduling 
and 759 general scheduling), were listed. The current legal status of Designated Substances, including SCs, is 
provided on the website of the Ministry of Health, Labour, and Welfare in Japan [154]. In 2016, eight SCs (e.g. 
AM-2201) were re-categorized from Designated Substances to narcotics in Japan.
7.4   Information sources
The legal status of SCs changes rapidly and varies between countries. Therefore, access to up-to-date regu-
latory information is essential. The websites of the United States Drug Enforcement Administration (DEA) 
(www.dea.gov) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (www.emcdda.
europa.eu), for example, provide information on the current legal status of SCs and other NPS in various 
regions. The United Nations Office on Drugs and Crime (UNODC) (www.unodc.org) established the Early 
Warning Advisory (EWA) on NPS, including SCs, which serves as a monitoring tool and knowledge hub offer-
ing information on NPS trends and national legislative responses, as well as technical information [155].
8   Conclusions
NPS represent a formidable challenge for forensic scientists, medical personnel, public health officials, leg-
islators, and law enforcement. The SC class of substances is particularly complex, as the chemical composi-
tion and diversity of marketed products changes rapidly and potency trends of identified compounds have 
increased since their first emergence in 2008. Use and abuse of these products have been linked to adverse 
events worldwide, including cardiotoxicity; psychosis, seizures, and other psychotropic effects; and, in 
certain cases, suicide or death.
In addition to informing the public about the health threat that these substances pose, resources must 
be allocated to scientific research in the area of SCs investigation. This includes, but is not limited to, epi-
demiological surveys of cannabinoid users, pharmacological and toxicological research, animal studies to 
evaluate abuse potential, and ongoing development of laboratory analytical methods for the identification of 
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markers in biological samples of intoxicated patients. Additionally, a search for the treatment of cannabinoid 
addiction and withdrawal symptoms is an urgent medical priority. It is also necessary to determine the most 
appropriate means of banning substances so as to discourage widespread distribution. This necessitates col-
laboration between scientists as well as the individuals responsible for assuring the health and well-being of 
societies worldwide.
 Acronyms
The following is a list of acronmys used in the preceeding text.
2-AG 2-arachidonoylglycerol
AEA arachidonolyethanolamine
BBB Blood-Brain Barrier
c-AMP Cyclic-Adenosine Monophosphate
CB Cannabinoid Receptor
CBRI Cannabinoid Reuptake Inhibitors
CES Carboxylesterase
CP Charles Pfizer
CYP450 Cytochrome P450
DEA Drug Enforcement Administration
DUID Driving Under the Influence of Drugs
EC Endocannabinoid
EMCDDA European Monitoring Centre for Drugs and Drug Addiction
EWA Early Warning Advisory
FAAH Fatty Acid Amide Hydrolase
FT-IR Fourier Transform-Infrared
GC-MS Gas Chromatography-Mass Spectrometry
Gi Inhibitory G-protein
GPR55 G-Protein Coupled Receptor 55
GTP Guanosine-Triphosphate
HLM Human Liver Microsome
HR-MS/MS High Resolution-Tandem Mass Spectrometry
IUPAC International Union of Pure and Applied Chemistry
JWH John W. Huffman
Ki Binding Affinity
LC-MS/MS Liquid Chromatography-Tandem Mass Spectrometry
LOD Limit of Detection
LOQ Limit of Quantification
MAGL Monoacylglycerol Lipase
NMR Nuclear Magnetic Resonance
NPS Novel Psychoactive Substances
NT Neurotransmitter
PET Positron Emission Tomography
PMR Post-Mortem Redistribution
SAR Structure-Activity Relationship
SC Synthetic Cannabinoid
TOF Time-of-Flight
TRPV1 Transient Receptor Potential Vanillinoid Type 1
UDP Uridine Diphosphate
UGT UDP-Glucuronosyltransferase
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UHPLC-MS/MS  Ultra High Performance Liquid Chromatography-Tandem Mass Spectrometry
UNODC United Nations Office on Drugs and Crime
Δ9-THC, THC Δ9-tetrahydrocannabinol
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